Volume 4, Issue 2, Page 1 (February 2009)
3 of 24
PREVIEW
FULL TEXT
FULL-TEXT PDF (383 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
Kinase inhibitors and antiangiogenic drugs may offer the first real hope of treating differentiated metastatic thyroid cancer, and seem to be especially effective in tumors exhibiting the B-type Raf kinase mutation.
PII: S1558-0164(09)70035-5
doi:10.1016/S1558-0164(09)70035-5
© 2009 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.